PYXS · Pyxis Oncology, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements were issued.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| confirmed objective response rate | 46% | December 2025 | — |
| disease control rate | 92% | December 2025 | — |
| target enrollment | 40 | 1Q26 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PYXS
this stock
Pyxis Oncology, Inc.
|
$256.06M | +193.0% | -14.2% | — | 5.0% |
|
ONC
BeOne Medicines Ltd.
|
$535.83B | +24.0% | +22179.2% | 823.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +21.8% | +46.2% | 30.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.27B | +8.9% | +20.8% | 20.3 | 3.3% |
|
ARGX
Argenx SE
|
$61.75B | +22.8% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PYXS | +6.0% | +33.2% | +121.7% | +27.2% | +193.0% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +6.4% | +30.3% | +110.1% | +24.2% | +180.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.